PureHealth profit climbs 14.1% to 1.8 billion dirhams on overseas push

The latest:

Net profit at Abu Dhabi-listed PureHealth Holding reached 1.8 billion dirhams in the first nine months of 2026, a 14.1% increase, as group revenue rose 11.5% to 22.4 billion dirhams. EBITDA climbed 20.4% to 4.2 billion dirhams and the margin widened to 18.6% from 17.3%, which the group attributed to operating efficiency and a larger contribution from higher-margin international operations.

Details:

• The growth drivers: PureHealth said revenue growth came from the consolidation of HealthCare Hellenic in Greece and Cyprus, which contributed roughly 2.3 billion dirhams, alongside a 5.3% rise at Circle Health in the United Kingdom and 11.7% growth in the insurance segment.
• International care: Revenue from the international care portfolio jumped 53% to 7.3 billion dirhams, according to the results. EBITDA for that portfolio rose 63% to 1.6 billion dirhams, with the margin improving to 22.3% from 20.8% a year earlier.
• The UK and Greece: Circle Health’s 5.3% revenue gain was driven by a higher share of inpatients requiring more intensive levels of care, the group said. HealthCare Hellenic recorded a 6% increase in patient numbers, attributed to higher outpatient visits.
• The UAE drag: Reported care revenue in the UAE fell 9.2% to 8.7 billion dirhams. PureHealth linked the decline to the revenue recognition mechanism tied to the unified procurement programme, the exclusion of intercompany transactions, and weaker first-quarter patient visits. Adjusted revenue rose 6% to 10.1 billion dirhams.
• Domestic recovery: Volumes improved after the first quarter, with outpatient visits up 9% and inpatient numbers up 13%. Operational capacity rose to 3,543 beds from 3,433, with occupancy at 76%. Domestic care EBITDA rose 3% to 1.74 billion dirhams, margin at 20% versus 17.7%.
• Insurance and Daman: Insurance revenue rose 11.7% to 6.4 billion dirhams on renewals, disciplined pricing and new business. Gross written premiums increased 14% to 6.8 billion dirhams, members rose 2% to about 3.4 million, and processed claims rose 6% to 43.2 million.
• Daman’s expansion: Daman widened its range into property and liability cover, booking 166 million dirhams in written premiums, supported by product development, partnerships and a dedicated SME line. Its net profit rose 3.9% to 667 million dirhams as it kept investing to build market share.
• Chairman’s framing: Kamal Al Mazmi, chairman of PureHealth, said the HealthCare Hellenic consolidation widened operations in Greece and Cyprus while Circle Health continues developing its UK business, diversifying the earnings base and deepening the group’s presence in established healthcare markets.
• CEO on operations: Group chief executive Shaista Asif said Circle Health expanded in the UK under an agreement to manage existing laboratories belonging to Uni Labs Limited, strengthening integration between diagnostics and hospitals. She said investment in specialty care, clinical capability and UAE capacity is starting to deliver returns.
• Technology: Asif said the group is continuing to embed artificial intelligence and digital solutions across clinical care pathways, procurement and patient communication, with the stated aim of improving service delivery, reducing operational complexity and easing patient access.

Background:

PureHealth trades on the Abu Dhabi Securities Exchange under the ticker PUREHEALTH. Its portfolio spans hospitals and care operations in the UAE, the United Kingdom through Circle Health, and Greece and Cyprus through HealthCare Hellenic, alongside the insurance business operated by Daman.

Between the lines:

The headline profit growth sits alongside a 9.2% decline in reported UAE care revenue, meaning the lift came largely from abroad. With international care revenue up 53% and carrying a 22.3% margin against 20% domestically, the earnings mix is tilting outward. Domestic volumes are recovering, but the recovery shows in bed occupancy and visit counts rather than reported revenue.

What’s next

Full-year 2026 results will show whether the UAE adjusted revenue recovery holds and whether HealthCare Hellenic sustains its contribution across a complete reporting year, alongside the rollout of the Uni Labs laboratory management agreement.